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PROGNOSTIC SIGNIFICANCE OF LEUKEMIC SUBCLONES
IDENTIFIED BY MULTIPARAMETER FLOW CYTOMETRY
The paper in this issue by Johnsen et al. ‘‘Clinical
impact of leukemic blast heterogeneity at diagnosis in
cytogenetic intermediate-risk acute myeloid leukaemia,’’
deals with an important issue that is central to the role
played by persistent leukemic cells in acute myeloid
leukemia.
Specifically, the heterogeneity of leukemic blasts is
thought to have significant relationship to the prognosis
of the disease; this is demonstrated by numerous studies
recently published in our journal at the cytogenetic and
molecular level as well as by documented immunophe-
notypic variations found in the malignant cells
(1,2,3,4,5). Interestingly, there is growing evidence that
malignant cells and stem cells traffic similarly and may
share a common niche (6). Johnsen’s paper demon-
strates that leukemic cancer stem cells share surface
molecules in common with normal stem cells, and both
cell types are characterized by high self-renewal and plu-
ripotency. The persistence of leukemic cancer stem cells
is considered to be essential in the maintenance of acute
myeloid leukemia and its relapse. Recent advances in
this area focus on the development of new drugs to
eradicate leukemic stem cells responsible for sustaining
leukemic growth. It is also clear that for improved treat-
ment results more knowledge about malignant stem cells
is required, and further studies are needed to clarify this
issue. A flow cytometric protocol enabling discrimina-
tion of myeloid leukemia stem cells from their normal
counterpart is essential in this challenging field, which
these authors have provided greater insight into.
CD300A SUPPRESSES BASOPHIL DEGRANULATION
Although not often identified in great numbers in the
normal human circulation, the critical role of basophils
has become an increasingly active area of study for the
part they play in both allergy and malignancy and is an
area ripe for study by cytometry (7,8,9). Our Clinical
Cytometry Journal readership has been most fortunate in
benefitting from the excellent contributions of a very
active and excellent group of investigators at the Ant-
werp University Hospital who have been focusing a
great deal of effort in this area (10,11). Normal basophil
activity and degranulation is a highly regulated process
that depends on the interaction of competing activating
and inhibitory signals. In this issue, the contribution
‘‘CD300a is expressed on human basophils and seems to
inhibit IgE/FcRI-dependent anaphylactic degranulation,’’
by Verwiej et al. begins to unravel those mechanisms
that lead to basophil inhibitory signals related to the
CD300a receptor. The ITM-containing CD300a is not spe-
cific to the basophil, but is also found on numerous leu-
kocytes and dendritic cells; how CD300a impacts all of
these various cell-types remains to be fully elucidated.
THE POWER OF A POLYCHROMATIC APPROACH TO
PAUCI-CELLULAR CEREBRAL SPINAL FLUID SPECIMENS
Flow cytometry has been shown to be a very sensitive
and effective modality for the characterization of cells
found in cerebrospinal fluid (12,13,14). When very few
cells are available for immunophenotypic analysis, poly-
chromatic flow cytometry truly provides benefit to clini-
cal care. Such analysis is more statistically robust and
medically relevant because increased numbers of patient
cells can be interrogated by more monoclonal antibod-
ies, at the same time. In this issue Alessandra et al. dem-
onstrate this principle expertly in a 10-antibody single-
tube approach for the analysis of cerebrospinal fluid for
B-cell malignancy. In this study, specimens that had
fewer than 10 cells/ml were compared by conventional
cytology to a polychromatic approach and an increased
sensitivity of the cytometric approach was observed.
THE PROGNOSTIC RELEVANCE OF CD8 CO-EXPRESSION ON
CHRONIC LYMPHOCYTIC LEUKEMIA
Malignant cells may express cell surface antigens which
are not characteristic of their cell type. Such observations
have been thought variously as combinations of either
our incomplete understanding of normal differentiation
states, lineage ‘‘infidelity’’ or perhaps perturbations at the
stem-cell level that manifest themselves in the further dif-
ferentiated neoplastic cell. While such uncharacteristic
expression is common in less well-differentiated hemato-
poietic malignancies such as acute myeloid and lympho-
blastic leukemia, it is not often observed in chronic lym-
phocytic leukemia. Most recent attention in chronic lym-
phocytic leukemia has been focused specifically on
improvements in the prognostic significance of ZAP-70
expression (15,16) and the relevance of monoclonal B-cell
proliferation to chronic lymphocytic leukemia, so much
so that special issues of our Journal have been previously
fully devoted to these topics (17,18). Those involved clini-
cal diagnostics for sufficient years have noticed that infre-
quently, CD8 was co-expressed on chronic lymphocytic
leukemia cells. It was speculated that the ephemeral inci-
dence of such expression might relate to simply ‘not look-
ing’ systematically for CD8 expression on the malignancy
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(19). In this issue, in evaluating 5,523 patients, Kern et al.
have done an excellent job of illuminating the relation-
ship between CD8 expression, IGHV status, ZAP-70 and
CD38 co-expression and how these all inter-relate to the
prognostic status of the patient.
PHOSPHO-FLOW CYTOMETRY FOR THERAPEUTIC DRUG
MONITORING
The mammalian target of rapamycin (mTOR) pathway
plays a critical role in the regulation of mRNA translation
and is thus involved in cell cycle progression, prolifera-
tion, angiogenesis, and cellular survival pathways. Inhibi-
tors of the mTOR pathway, such as sirolimus, are used
as immunosuppresives clinically in combinations with
cyclosporine, tacrolimus, mycophenolate acid and corti-
costeroids to prevent the rejection of transplanted solid
organs. In the administration of all such therapies, under-
standing the pharmacodynamics is critical to ascertain
the appropriate dosages of the therapies administered.
In the very exciting study ‘‘Assay validation of phospho-
rylated S6 ribosomal protein for a pharmacodynamic
monitoring of mTOR-inhibitors in peripheral human
blood,’’ Dieterlen et al. examined the presence of phos-
phorylated S6 ribosomal protein (p-S6RP) in T-cells to
measure the impact of the immunosuppressive effects of
sirolimus therapy. These investigators validated an in
vitro test and found that phospho-flow cytometry offers
an excellent way to identify functionally activated T-cell
populations by the presence or absence of phosphoryl-
ated proteins within those cells.
CELL SIGNALING INFORMATION IN AML CAN BE STUDIED
FROM CIRCULATING BLOOD SPECIMENS
By combining multiparameter flow cytometry with sin-
gle cell nucleotide profiling, a dynamic and quantitative
view of intracellular functional events over time can be
appreciated. This technique is useful as a way to under-
stand the results of therapy or relapse risks in AML. In
this issue Cesano et al. in the article ‘‘Functional path-
way analysis in acute myeloid leukemia using single cell
network profiling (SCNP) assay: effect of specimen
source (bone marrow or peripheral blood) on assay read-
outs,’’ compared peripheral blood to bone marrow from
46 patients with AML and determined that blood proteo-
mic results correlated well with those obtained from the
marrow. These results suggest that blood specimens can
be informative to the direction of therapy when obtain-
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